Alzamend Neuro Inc
ALZNHealthcare|Biotechnology|US
$1.41
-0.14 (-9.03%)
Tangible Book / Share
$1.30
Cash / Share
$1.70
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05834296 Study in Subjects With Mild-to-Moderate Alzheimer's Dementia | Alzheimer Disease | P1P2 | Active | 30 | RCT, Double-blind | ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo |
| NCT07540338 A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder | Bipolar I Disorder | P1P2 | Recruiting | 20 | RCT, Open-label | AL001, Lithium carbonate |
| NCT05363293 Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects | Alzheimer's Disease, Healthy Non-elderly and Elderly Adults | P1P2 | Completed | 65 | RCT, Double-blind | AL001 |
| NCT06921590 A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects | Pharmacokinetics, Neurology | P1 | Completed | 15 | RCT, Open-label | AL001, Lithium Carbonate Capsule |